PMID- 17803444
OWN - NLM
STAT- MEDLINE
DCOM- 20071031
LR  - 20070906
IS  - 1084-9785 (Print)
IS  - 1084-9785 (Linking)
VI  - 22
IP  - 4
DP  - 2007 Aug
TI  - Review: dendritic cell-based vaccine in the treatment of patients with advanced 
      melanoma.
PG  - 501-7
AB  - Traditionally, immunology is mainly about the study of the immune response 
      against foreign antigens, such as bacteria and viruses. Accordingly, tumor cells 
      expressing alien or altered antigens make the attractive targets against which 
      cancer immunology is initiated. However, recent comprehensive studies 
      demonstrated that most prevalent antigens recognized by our immune system in 
      cancer are those shared, nonmutated self-antigens expressed also by normal tissue 
      cells. Thus, how to break the self-tolerance and avoid the concomitant 
      autoimmunity remain the two challenges in cancer immunology. Dendritic cells 
      (DCs) are the most effective antigen-presenting cells. They are capable of 
      capturing, processing, and presenting antigens to T- and B-cells. This feature 
      targets dendritic cells as the ideal candidates for breaking self-tolerance in 
      cancer immunology. Clinical trials have demonstrated that dendritic cells are 
      effective messengers. They circulate around the body and stimulate cytotoxic 
      T-lymphocytes to clear tumor cells. Vaccination with DCs led to a clinical 
      response in patients with melanoma, specifically those without significant 
      autoimmunity. In this paper, we will examine the strategies and efficacies of 
      DC-based vaccinations in the treatment of patients with melanoma.
FAU - Zhang, Sheng
AU  - Zhang S
AD  - Department of Medical Oncology, First People's Hospital, Shanghai Jiaotong 
      University, Shanghai, China. wozhangsheng@hotmail.com
FAU - Wang, Qing
AU  - Wang Q
FAU - Miao, Beiping
AU  - Miao B
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (Antigens)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigens/immunology
MH  - Cancer Vaccines/*immunology/*therapeutic use
MH  - Cell Differentiation/immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Melanoma/*immunology/pathology/*therapy
MH  - Neoplasm Staging
RF  - 42
EDAT- 2007/09/07 09:00
MHDA- 2007/11/01 09:00
CRDT- 2007/09/07 09:00
PHST- 2007/09/07 09:00 [pubmed]
PHST- 2007/11/01 09:00 [medline]
PHST- 2007/09/07 09:00 [entrez]
AID - 10.1089/cbr.2007.354 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2007 Aug;22(4):501-7. doi: 10.1089/cbr.2007.354.